For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo Receives Additional Dosage Regimen Approval in Japan for
Long-acting Neuraminidase Inhibitor Inavir® Dry Powder Inhaler 20mg

Tokyo, Japan (August 26, 2016) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has received additional dosage regimen approval in Japan for influenza A and B antiviral agent, Inavir® Dry Powder Inhaler 20mg (JAN: Laninamivir Octanoate Hydrate) for the prevention of influenza, in single inhalation doses of 40 mg for adults and children 10 years of age or older, and single inhalation doses of 20 mg for children younger than 10 years of age.

Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo for the prevention and treatment of influenza A and B. These additional dosage regimen approvals make it possible to administer single inhalation doses of this drug to adults and children for the prevention of influenza virus infection.

The additional dosage regimen approvals of this influenza antiviral agent will allow Daiichi Sankyo to offer a new choice of medicines to all patients and medical personnel, allowing Daiichi Sankyo to further contribute to the health of society.
## Product overview

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Inavir® Dry Powder Inhaler 20mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of approval for partial changes</td>
<td>August 26, 2016</td>
</tr>
<tr>
<td>Indications and usage</td>
<td>Treatment and prevention of influenza A and B viruses</td>
</tr>
</tbody>
</table>
| Dosage and administration (additional approval underlined) | 1. For the treatment of influenza virus  
    Adults: A single inhaled dose of 40 mg of laninamivir octanoate.  
    Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate.  
    If 10 years old or older, a single inhaled dose of 40 mg of laninamivir octanoate.  
    2. For the prevention of influenza virus  
    Adults: A single inhaled dose of 40 mg of laninamivir octanoate.  
    Alternatively, daily single inhaled dosage of 20 mg of laninamivir octanoate for two days as well.  
    Children: If less than 10 years old, a single inhaled dose of 20 mg of laninamivir octanoate.  
    If 10 years old or older, a single inhaled dose of 40 mg of laninamivir octanoate.  
    Alternatively, daily single inhaled dosage of 20 mg of laninamivir octanoate for two days as well. |